Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 13/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | GLA | P06280 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CD74 | P04233 | 1/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24145151 | 0.88 | APP (0.77) | APPCYP1A2KDM4EGLAGAA | |
| SCHEMBL21211676 | 0.86 | APP (0.70) | APPCYP1A2KDM4EGLAGAA | |
| SCHEMBL9881038 | 0.86 | APP (0.64) | APPCYP1A2KDM4EGLAGAA | |
| SCHEMBL18932158 | 0.86 | APP (0.74) | APPCYP1A2KDM4EGAAALDH1A1 | |
| SCHEMBL22901183 | 0.85 | APP (0.83) | APPCYP1A2CD74MIF | |
| SCHEMBL15217855 | 0.85 | APP (0.65) | APPCYP1A2KDM4EGLAGAA | |
| SCHEMBL12189748 | 0.84 | APP (0.67) | APPCYP1A2KDM4EGLAGAA | |
| SCHEMBL19627052 | 0.84 | APP (0.64) | APPCYP1A2KDM4EGLAGAA | |
| SCHEMBL563392 | 0.84 | APP (1.00) | APPCYP1A2KDM4ECA12CA9 | |
| SCHEMBL31115697 | 0.84 | APP (1.00) | APPCYP1A2KDM4ECA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3894018-B1 | TOPICAL, ISOTONIC COMPOSITIONS FOR GENITAL USE | GLYCIOME LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4719594-A1 | DECREASING ACINETOBACTER POPULATIONS IN THE MICROBIOME | Glyciome, LLC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260076922-A1 | DECREASING ACINETOBACTER POPULATIONS IN THE MICROBIOME | GLYCIOME LLC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12576096-B2 | Topical, isotonic compositions for genital use | GLYCIOME, LLC (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4594516-A2 | SYSTEMS AND METHODS FOR SCREENING OF LARGE GENE LIBRARIES | President and Fellows of Harvard College (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2024249580-A1 | DECREASING ACINETOBACTER POPULATIONS IN THE MICROBIOME | GLYCIOME, LLC (US) | 2024-12-05 | — | — | WO | disclosed |
| US-12083304-B2 | Kits for topical, isotonic compositions | GLYCIOME, LLC (US) | 2024-09-10 | — | — | US | disclosed |
| WO-2024073375-A2 | SYSTEMS AND METHODS FOR SCREENING OF LARGE GENE LIBRARIES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20230039637-A1 | MICROBIOME OPTIMIZATION | GLYCIOME, LLC (US) | 2023-02-09 | — | — | US | disclosed |
| WO-2022246115-A1 | APT1 AND APT2 INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2022-11-24 | — | — | WO | disclosed |
| US-6777243-B2 | MEASURING DETECTABLE SUBSTANCE BY USING AQUEOUS REACTION SYSTEM INCLUDING FORMATION REACTION OF DETECTABLE SUBSTANCE BASED ON CHEMICAL REACTION OF ANALYTE CONTAINED IN SAMPLE; REACTING IN PRESENCE OF LAYERED INORGANIC COMPOUND | ARKRAY INC. (JP) | 2004-08-17 | — | — | US | disclosed |
| US-20030203503-A1 | Method for measuring substance and testing piece | FUKUOKA TAKAO (JP) | 2003-10-30 | — | — | US | disclosed |
| US-20030180183-A1 | Method for measuring substance and testing piece | FUKUOKA TAKAO (JP) | 2003-09-25 | — | — | US | disclosed |
| US-20030175985-A1 | Method for measuring substance and testing piece | FUKUOKA TAKAO (JP) | 2003-09-18 | — | — | US | disclosed |
| US-20030175984-A1 | Method for measuring substance and testing piece | FUKUOKA TAKAO (JP) | 2003-09-18 | — | — | US | disclosed |
| US-20030166295-A1 | Method for measuring substance and testing piece | FUKUOKA TAKAO (JP) | 2003-09-04 | — | — | US | disclosed |
| US-20030044316-A1 | Specimen having capability of separating solid component | ARKRAY INC. (JP) | 2003-03-06 | — | — | US | disclosed |
| EP-1271143-A1 | SPECIMEN HAVING CAPABILITY OF SEPARATING SOLID COMPONENT | ARKRAY, Inc. (JP) | 2003-01-02 | — | — | EP | disclosed |
| EP-0860695-A9 | METHOD OF MEASUREMENT OF MATERIAL AND TESTPIECE | KABUSHIKI KAISHA KYOTO DAIICHI KAGAKU (JP) | 2001-10-17 | — | — | EP | disclosed |
| EP-0860695-A1 | METHOD OF MEASUREMENT OF MATERIAL AND TESTPIECE | KABUSHIKI KAISHA KYOTO DAIICHI KAGAKU (JP) | 1998-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576096-B2 | Topical, isotonic compositions for genital use | MAN2B2, AP1S1, MAN2A1 | APP 4223/4885CYP1A2 910/4885KDM4E 4872/4885 |
| US-20260076922-A1 | DECREASING ACINETOBACTER POPULATIONS IN THE MICROBIOME | MAN2B2, ALG3, FUCA1 | APP 455/4885CYP1A2 151/4885KDM4E 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.